Skip to main content

Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.

Publication ,  Journal Article
Gaillard, S; Stearns, V
Published in: Breast Cancer Res
March 14, 2011

Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often lead to discontinuation of therapy. Ideally, the symptoms should be prevented or adequately treated. This review will focus on bone and musculoskeletal side effects of aromatase inhibitors, including osteoporosis, fractures, and arthralgias. Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Breast Cancer Res

DOI

EISSN

1465-542X

Publication Date

March 14, 2011

Volume

13

Issue

2

Start / End Page

205

Location

England

Related Subject Headings

  • Tamoxifen
  • Postmenopause
  • Osteoporosis
  • Oncology & Carcinogenesis
  • Musculoskeletal System
  • Humans
  • Female
  • Breast Neoplasms
  • Bone and Bones
  • Arthralgia
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gaillard, S., & Stearns, V. (2011). Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res, 13(2), 205. https://doi.org/10.1186/bcr2818
Gaillard, Stéphanie, and Vered Stearns. “Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.Breast Cancer Res 13, no. 2 (March 14, 2011): 205. https://doi.org/10.1186/bcr2818.
Gaillard, Stéphanie, and Vered Stearns. “Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.Breast Cancer Res, vol. 13, no. 2, Mar. 2011, p. 205. Pubmed, doi:10.1186/bcr2818.

Published In

Breast Cancer Res

DOI

EISSN

1465-542X

Publication Date

March 14, 2011

Volume

13

Issue

2

Start / End Page

205

Location

England

Related Subject Headings

  • Tamoxifen
  • Postmenopause
  • Osteoporosis
  • Oncology & Carcinogenesis
  • Musculoskeletal System
  • Humans
  • Female
  • Breast Neoplasms
  • Bone and Bones
  • Arthralgia